VISTA抑制劑的全球市場:臨床試驗，醫藥品開發機會，專利的洞察(2025年)

Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025

出版日期: 2025年04月01日 | 出版商:

KuicK Research | 英文 75 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

近年來，癌症免疫治療領域發生了顯著變化，免疫檢查點抑制劑徹底改變了各種惡性腫瘤的治療方法。隨著第一代免疫檢查點抑制劑（如派姆單抗和納武單抗）的巨大成功，研究人員目前正致力於識別新的免疫檢查點蛋白。 T 細胞活化的 V 結構域免疫球蛋白抑制劑 (VISTA) 已成為此創新領域的下一代目標。

VISTA 是一種關鍵的免疫檢查點蛋白，在控制免疫反應中起著微妙的作用，尤其是在腫瘤微環境中。與 PD-1 和 CTLA-4 等研究更廣泛的檢查點分子不同，VISTA 是一個相對較新的靶點，具有尚未開發的潛力。越來越多的研究認識到 VISTA 在調節 T 細胞活化和抑制抗腫瘤免疫反應中的重要性，這使得 VISTA 成為標靶免疫治療策略的有趣候選人。

目前的免疫療法前景與現有免疫檢查點抑制劑的顯著成功相似，這表明針對 VISTA 的療法具有巨大的前景。 PD-1 和 CTLA-4 抑制劑的突破為更複雜、更精確的免疫調節幹預鋪平了道路。這些先例為探索 VISTA 等新型檢查點標靶提供了強有力的科學驗證和投資者信心，預示著變革性治療方法的潛力。

VISTA 標靶治療中最有前景的進展之一是 CA-170，這是由 Aurigene Oncology 和 Curis 開發的創新口服小分子。該化合物是一種優雅的雙重抑制劑，同時針對 VISTA 和 PD-L1，與傳統的基於抗體的方法相比具有多種吸引人的優勢。這種分子可以口服，有可能減少併發症並使免疫相關不良事件更易於控制，這使其有別於傳統的免疫治療策略。

Aurigene Oncology 和 Curis 之間的策略合作凸顯了人們對 VISTA 標靶療法的極大興趣和商業潛力。透過在不同地區劃分開發權，此次合作凸顯了全球科學界對 VISTA 治療潛力的認可。正在進行的後期臨床試驗，特別是研究 CA-170 對非小細胞肺癌療效的 2b/3 期研究，代表著了解該分子臨床效用的重要里程碑。

臨床前和早期研究揭示了 VISTA 複雜的免疫調節機制。與幾種檢查點蛋白不同，VISTA 表現出抑制 T 細胞反應的獨特特性，這對癌症免疫療法具有微妙的意義。初步研究表明，抑制 VISTA 有可能重振抗腫瘤免疫反應，為現有的檢查點阻斷策略提供補充或替代方法。

缺乏經批准的 VISTA 標靶療法對研究人員和藥物開發人員來說既是課題也是機會。該治療領域的未知領域允許採用創新方法並允許創造性地探索 VISTA 的潛在機制。研究人員對 VISTA 克服其他檢查點抑制劑所觀察到的抗藥性機制的潛力特別感興趣，這可能為患有難治性惡性腫瘤的患者帶來新的希望。

隨著科學界不斷揭示 VISTA 在免疫調節中的複雜作用，預計未來幾年研究和臨床開發將會加速。開發能夠更精確地調節免疫反應的標靶療法的可能性代表了個人化醫療的重大進步。儘管課題依然存在，但基礎研究和正在進行的臨床研究為 VISTA 標靶治療策略描繪了樂觀的前景。

本報告提供全球VISTA抑制劑市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，各地區趨勢，及加入此市場的主要企業競爭情形等資訊。

First VISTA Inhibitor Drug Approval By 2028
US Dominating Global VISTA Inhibitor Clinical Trials Landscape
Insight On Ongoing Clinical Trials By Company, Country, Indication & Phase
Key Drugs Clinical Study Initiation & Completion Year Overview
Global & Regional Market Development Insight By Indication
Global VISTA Inhibitors Market Dynamics & Competitive Landscape

The landscape of cancer immunotherapy has witnessed remarkable transformations in recent years, with immune checkpoint inhibitors revolutionizing treatment approaches for various malignancies. With the massive success of first generation immune checkpoint inhibitors, such as pembrolizumab and Nivolumab, researchers have now focused their efforts in identifying newer immune checkpoint proteins. Among the emerging next-generation targets in this innovative field is the V-domain immunoglobulin suppressor of T cell activation (VISTA), which represents a promising yet under-explored avenue for potential therapeutic interventions across a range of indications.

VISTA, a critical immune checkpoint protein, plays a nuanced role in regulating immune responses, particularly within the tumor microenvironment. Unlike more extensively studied checkpoint molecules like PD-1 and CTLA-4, VISTA remains a relatively nascent target with significant untapped potential. Researchers have increasingly recognized its importance in modulating T cell activation and suppressing anti-tumor immune responses, making it an intriguing candidate for targeted immunotherapeutic strategies.

The current immunotherapy landscape demonstrates considerable promise for VISTA targeted approaches, drawing parallels with the remarkable success of existing immune checkpoint inhibitors. The groundbreaking achievements of PD-1 and CTLA-4 inhibitors have paved the way for more sophisticated and precise immunomodulatory interventions. These precedents provide robust scientific validation and investor confidence in exploring novel checkpoint targets like VISTA, suggesting a potentially transformative therapeutic approach.

Among the most promising developments in VISTA targeted therapy is CA-170, an innovative oral small molecule developed by Aurigene Oncology and Curis. This compound represents a sophisticated dual inhibitor targeting both VISTA and PD-L1, offering several compelling advantages over traditional antibody-based approaches. The molecule's oral administration format, reduced complexity, and potential for more manageable immune-related adverse events distinguish it from conventional immunotherapeutic strategies.

The strategic collaboration between Aurigene and Curis highlights the significant interest and potential commercial viability of VISTA targeted therapies. By dividing development rights across different geographical regions, the partnership underscores the global scientific community's recognition of VISTA's therapeutic potential. The ongoing late-phase clinical trials, particularly the phase 2b/3 studies investigating CA-170's efficacy in non-small cell lung cancer, represent a critical milestone in understanding the molecule's clinical utility.

Preclinical and early stage research has unveiled VISTA's complex immunomodulatory mechanisms. Unlike some checkpoint proteins, VISTA exhibits unique characteristics in suppressing T cell responses, suggesting nuanced implications for cancer immunotherapy. Preliminary studies indicate that VISTA's inhibition could potentially reinvigorate anti-tumor immune responses, offering a complementary or alternative approach to existing checkpoint blockade strategies.

The lack of approved VISTA-targeted therapies presents both a challenge and an opportunity for researchers and pharmaceutical developers. The uncharted nature of this therapeutic domain invites innovative approaches and allows for creative exploration of VISTA's potential mechanisms. Researchers are particularly intrigued by VISTA's potential in overcoming resistance mechanisms observed with other checkpoint inhibitors, potentially offering new hope for patients with treatment-resistant malignancies.

Scientific interest in VISTA extends beyond oncology, with emerging research suggesting potential applications in autoimmune disorders and inflammatory conditions. This broader therapeutic landscape further amplifies the molecule's significance and underscores the importance of continued investigative efforts. The multifaceted nature of VISTA's immunomodulatory functions presents a complex yet exciting frontier for translational research.

As the scientific community continues to unravel VISTA's intricate roles in immune regulation, the coming years are likely to witness accelerated research and clinical development. The potential for developing targeted therapies that can modulate immune responses with greater precision represents a significant advancement in personalized medicine. While challenges remain, the foundational research and ongoing clinical investigations paint an optimistic picture for VISTA-targeted therapeutic strategies.

1. VISTA As Emerging Immune Checkpoint

1.1 What Is VISTA Inhibition?
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism Of Action Of VISTA Inhibitors

2. VISTA As Inhibitory & Costimulatory Checkpoint

2.1 VISTA As Inhibitory Immune Checkpoint
2.2 VISTA As Costimulatory Checkpoint
2.3 VISTA Inhibition v/s Conventional Immune Checkpoint Inhibitors

3. Significance Of VISTA In Disease Progressiopn & Cure

3.1 Role Of VlSTA In Facilitating Cancer Progression
3.2 VISTA As Potential Cancer Biomarker
3.3 VISTA As Therapeutic Target In Autoimmune Diseases

4. Global VISTA Inhibitors Market & Clinical Development Outlook

4.1 Current Scenario
4.2 Future Opportunities

5. VISTA Targeted Therapies Trends & Clinical Innovation By Indication

5.1 Solid Cancers
5.2 Hematological Cancers
5.3 Autoimmune & Inflammatory Disorders

6. VISTA Targeted Therapies Trends & Clinical Innovation By Region

6.1 US
6.2 Europe
6.3 India
6.4 Australia

7. Global VISTA Inhibitors Clinical Trials Overview

7.1 By Country
7.2 By Indication
7.3 By Organization
7.4 By Phase

8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase III

9. Global VISTA Inhibitors Market Dynamics

9.1 Market Drivers
9.2 Market Challenges

10. Competitive Landscape

10.1 Aurigene Discovery Technologies
10.2 Curis
10.3 Hummingbird Bioscience
10.4 Kineta
10.5 PharmAbcine
10.6 Sensei Biotherapeutics

簡介目錄圖表

List of Figures

Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 2-1: VISTA - Role In Cancer Immunotherapy
Figure 2-2: VISTA - Role In Autoimmune Diseases
Figure 2-3: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
Figure 3-1: VISTA Interaction With Immune Cells
Figure 3-2: VISTA - Mechanisms Of Immune Suppression
Figure 3-3: Dual Role Of VISTA In Cancer
Figure 3-4: VISTA As Predictive Biomarker
Figure 3-5: Autoimmune Diseases - VISTA Agonism
Figure 4-1: Future Market Opportunities
Figure 5-1: Solid Tumors - VISTA Role In Tumor Immune Evasion
Figure 5-2: SNS-101-2-1 Phase 1/2 (NCT05864144) Study - Initiation & Completion Year
Figure 5-3: HMBD-002-V4C26-01 Phase 1/2 (NCT05082610) Study - Initiation & Completion Year
Figure 5-4: Hematological Cancers - Mechanisms Of Immune Evasion By VISTA
Figure 5-5: Autoimmune & Inflammatory Disorders - VISTA As Ligand On APCs
Figure 5-6: Autoimmune & Inflammatory Disorders - VISTA As Receptor On T Cells
Figure 5-7: Kings College London & Dartmouth College VISTA Patent - Grant & Expiration Year
Figure 6-1: MarkV-01/KEYNOTE-E80 Phase 1 (NCT05957081) Study - Initiation & Completion Year
Figure 7-1: Global - Number Of VISTA Inhibitors In Clinical Trials By Country, 2025
Figure 7-2: Global - Number Of VISTA Inhibitors In Clinical Trials By Indication, 2025
Figure 7-3: Global - Number Of VISTA Inhibitors In Clinical Trials By Organization, 2025
Figure 7-4: Global - Number Of VISTA Inhibitors In Clinical Trials By Phase, 2025
Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints